MHRA Approves Guselkumab for Inflammatory Bowel Disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya, Janssen-Cilag Limited) for use in adults with Crohn's disease and ulcerative colitis (UC).
The drug is already licensed in the UK for plaque psoriasis and psoriatic arthritis.
The new indication covers patients with moderately to severely active Crohn's disease or UC who have not responded to other treatments or have experienced unacceptable side effects.
Guselkumab is a monoclonal antibody (IgG1-lambda) that inhibits interleukin-23 (IL-23)—a natural cytokine associated with inflammatory and immune responses—by selectively binding to its p19 subunit. This inhibits the proinflammatory actions of IL-23, thereby decreasing cytokine and chemokine release.
The European Medicines Agency extended the drug's indications in March.
Crohn's Disease: Remission in More Than Half of Patients
The MHRA said that clinical trials showed that guselkumab reduced symptoms such as diarrhoea and abdominal pain in patients with Crohn's disease.
Three studies involving around 1400 patients found that up to 56% achieved clinical remission after 12 weeks of treatment. In comparison, 15%-22% of patients on placebo reached remission.
Endoscopic response, indicating reduced intestinal inflammation, was seen in up to 41% of patients treated with guselkumab versus 11%-21% in the placebo group.
A follow up study published last year showed that 57%-75% of patients maintained remission to week 48, depending on the dose. Endoscopic remission at week 48 was reported in 17%-33% of treated patients.
Initial induction treatment is given by either intravenous infusion or injection every 4 weeks for three cycles. This is followed by maintenance therapy with subcutaneous injections every 4 or 8 weeks, depending on the induction phase response.
Pre-filled syringes or pens are available for self-administration.
Ulcerative Colitis: Long-Term Remission Achievable
In UC, guselkumab helps to reduce abdominal pain and inflammation of the intestinal lining, reducing fatigue and helping patients maintain normal activities.
According to the MHRA, 23% of patients receiving guselkumab achieved clinical remission after 12 weeks of induction treatment, compared with 8% on placebo.
With continued treatment, remission was reported in up to 50% of patients by week 44. In the placebo group, the remission rate was 19%.
A study extension, presented by the manufacturer at Digestive Disease Week this month, showed 72% of patients in clinical remission, with 99% of them remaining corticosteroid free for 8 or more weeks through to week 92. Among the 43% of trial patients in endoscopic remission at week 44, most (84%) maintained this outcome through to week 92.
Induction treatment for UC involves monthly intravenous infusions. Maintenance treatment is delivered by subcutaneous injection.
Treatment should be discontinued if there is no clinical response after 24 weeks.
Adverse Effects and Safety Monitoring
Guselkumab is associated with an increased risk of infections, particularly of the upper respiratory tract. Fungal and viral infections, such as tinea and herpes simplex, are also common.
Patients should be screened for tuberculosis before initiating treatment. Live vaccines are contraindicated during therapy.
Other commonly reported side effects include headache, injection site reactions, arthralgia, elevated liver enzymes, diarrhoea, and gastroenteritis.
Julian Beach, interim executive director of healthcare quality and access at the MHRA, said in a press release: 'We're assured that the appropriate regulatory standards of safety, quality, and efficacy for the approval of this new formulation have been met."
He added that the safety of guselkumab will be kept under close review. Healthcare professionals and patients are encouraged to report adverse reactions via the Yellow Card scheme.
A full list of side effects will be included in the Patient Information Leaflet and the Summary of Product Characteristics, available on the MHRA website within 7 days of approval.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Grandfather's simple changes reversed pre-diabetes diagnosis that left him 'petrified'
A 66-year-old grandfather who exercised daily was stunned to learn he was pre-diabetic — and he says making one small change to his eating habits helped reverse it. Dance teacher Will McKechnie, from Lytham St Annes, Lancashire, told SWNS he had always considered himself healthy. At 5 feet 10 inches tall and 167 pounds, he wore a medium-sized shirt, danced seven times a week, and didn't think twice about his daily snacks: a chocolate bar and a bag of chips. Experts Reveal Hidden Ways Sugar Accelerates Aging Beyond Just Weight Gain "I honestly thought I was really fit and healthy," McKechnie said. But after undergoing a free screening for people over 60 in May 2023, a routine blood test showed that his average blood sugar level was 6.2% — an indicator of pre-diabetes, according to SWNS. Read On The Fox News App McKechnie didn't find out until a year later, during an unrelated appointment, when his doctor reviewed the results. "I was so shocked and worried to hear I was pre-diabetic," he said. 'I'm A Neurologist — Here's Why Dementia Is Rising And How To Reduce Your Risk' McKechnie continued, "When he said it wouldn't be reversible over 48, I was terrified. I was petrified at the idea that I might be starting to have poor health." Determined to turn things around, McKechnie made some major changes — not only in what he ate, but how. He cut out the nightly chocolate and chips, started eating whole, nutritious foods, and began chewing his food much more slowly. Now, his lunch — a wholemeal chicken sandwich — takes him 40 minutes to eat. "I just have a very occasional treat now, and much smaller," McKechnie told SWNS. Golfer Phil Mickelson's Strict Weight Loss Diet: Doctor Shares What To Know His breakfast now consists of fruit, and a typical dinner includes boiled eggs, roasted peanuts, celery, cherry tomatoes, carrots and cucumber. By focusing on slower eating and more mindful food choices, McKechnie shed nearly 27 pounds, bringing him down to 142 pounds and a size small shirt. He also lost two inches off his waist — and, more importantly, his blood sugar dropped to 5.9% within nine months, SWNS reported. "I'm very determined," McKechnie said. He added, "If I set my mind to doing something, I'll do it, and I'm going to get my blood sugar even lower." The grandfather of four said he no longer battles sugar cravings and doesn't feel the urge to rush into stores for a chocolate fix. He also stays busy caring for his 18-month-old grandson and teaching two dance classes a week. McKechnie, who quit smoking in 1986 and stopped drinking in 2012, believes everyone should be proactive about checking their health — even if they look healthy on the outside. Click Here To Sign Up For Our Health Newsletter "Even if you have to pay for it, it's worth getting your blood sugar checked routinely," he told SWNS, adding, "It's much, much better to find out." For more Health articles, visit According to SWNS, McKechnie now says he feels stronger than ever and has "enormous amounts of energy." "I'm so relieved I had that test. It has changed my life and made me so much fitter."Original article source: Grandfather's simple changes reversed pre-diabetes diagnosis that left him 'petrified'
Yahoo
an hour ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
British tourist catches Legionnaires' disease in Greece
A British tourist is in hospital after catching a serious lung disease while on an all-inclusive holiday in Greece. Donna Jobling, from west Hull, contracted Legionnaires' disease on the island of Crete and is in intensive care. The 57-year-old, who husband Sid, 69, remains at her bedside, was travelling with easyJet Holidays, which said it had moved other customers out of the hotel where she was staying. "We're so sorry to hear that Ms Jobling is unwell, and we're continuing to support her and her family in every way we can," a spokesperson said. Legionella bug delays £41m health centre opening Ms Jobling has been in an intensive care unit at Venizeleio Hospital in Heraklion since 11 June, her niece Klaire Keita told the BBC. On 5 June she developed a chest infection which triggered acute respiratory failure and pneumonia, her niece added. "We just don't know what's going to happen. We're just trying to do the best we can for her," she said. Fighting back tears, Ms Keita added: "She is just the best person you could ever hope to meet." She said her aunt was "stable but under constant watch". Ms Jobling and her husband were holidaying with another couple, Paula and Nicholas Mason, also from Hull. They returned home on 12 June - the day the couples were meant to fly back together. Ms Mason, 52, said: "I felt awful having to leave my best friend there. "Donna has a heart of gold. She would do anything for anyone. We are all still in shock." Ms Mason said photographs of her friend taken at the start of the break showed her "looking really healthy". "Nicolas and Sid had booked the trip as a surprise for us women. Donna was really looking forward to it." Following Ms Jobling's diagnosis, the Greek health ministry issued a statement to hoteliers in Crete to "raise awareness among all those involved in monitoring the quality of water for human consumption especially with regard to Legionella". The source of the disease has not yet been identified but easyJet Holidays has moved other customers out of the hotel they were staying in, as a precaution. "We've also been in touch with customers who recently returned home from this hotel, to inform them of necessary guidance," a spokesperson said. "Our customers' safety and wellbeing is our top priority, and we'll continue to do all we can to support them." It is understood the hotel affected is currently working with local health authorities on the island. An emergency alert has been issued on the island by the European Centre for Disease Prevention and Control following the diagnosis. Legionnaires' disease is a lung infection most commonly contracted through the inhalation of water droplets containing Legionella bacteria. It is usually caught in places such as hotels, hospitals and office buildings from contaminated air conditioning systems, but can also be contracted from spa pools and hot tubs. Symptoms include shortness of breath, a high temperature and chest pain or discomfort, particularly when breathing or coughing. The disease can induce pneumonia and other respiratory illnesses, which can be life-threatening. Smokers, people over the age of 50 and those who are immunocompromised or have chronic lung conditions are at higher risk of developing the disease. A Foreign, Commonwealth & Development Office spokesperson said: "We are supporting the family of a British woman in hospital in Greece and are in contact with the local authorities." Legionella bug closed mental health ward - report
